Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study.

Abstract

The authors performed an open, randomized trial in patients with inclusion body myositis comparing 1) 12-month treatment with oral methotrexate 7.5 mg/week alone (MTX group) with 2) 12-month MTX treatment preceded by 7 days of IV anti-T-lymphocyte immunoglobulin treatment (ATG group). Eleven patients were randomized; 10 patients completed 12 months follow-up. Myometry showed that patients in the ATG group (n = 6) increased in mean muscle strength by 1.4% compared with the MTX group (n = 5), whose muscle strength decreased by 11.1% (p = 0.021).

• Authors: C Lindberg, E Trysberg, A Tarkowski, A Oldfors
• Journal: Neurology (Neurology) Vol. 61 Issue 2 Pg. 260-2 (Jul 22 2003) ISSN: 1526-632X [Electronic] United States
• PMID: 12874415 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Antilymphocyte Serum
• Immunosuppressive Agents
• Methotrexate

Topics

• Aged
• Aged, 80 and over
• Antilymphocyte Serum (therapeutic use)
• Autoimmune Diseases (therapy)
• Female
• Humans
• Immunosuppressive Agents (therapeutic use)
• Male
• Methotrexate (therapeutic use)
• Muscle Contraction
• Myositis, Inclusion Body (therapy)
• Pilot Projects
• Prospective Studies
• T-Lymphocytes (immunology)
• Treatment Outcome